741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620641
Title:
741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.
Authors:
Hubner, Richard A ( 0000-0002-7081-8823 ) ; Chen, L; Li, C; Bodoky, G; Dean, A; Lee, K; Cunningham, D; Siveke, J; Braiteh, F; de Jong, F; Belanger, B; Walls, R; Mody, P; von Hoff, D; Wang-Gillam, A
Affiliation:
Oncology, The Christie NHS Foundation Trust, Manchester
Citation:
741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone. 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620641
DOI:
10.1093/annonc/mdx369.124
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.124/4108827/741PPrognostic-value-of-baseline
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHubner, Richard Aen
dc.contributor.authorChen, Len
dc.contributor.authorLi, Cen
dc.contributor.authorBodoky, Gen
dc.contributor.authorDean, Aen
dc.contributor.authorLee, Ken
dc.contributor.authorCunningham, Den
dc.contributor.authorSiveke, Jen
dc.contributor.authorBraiteh, Fen
dc.contributor.authorde Jong, Fen
dc.contributor.authorBelanger, Ben
dc.contributor.authorWalls, Ren
dc.contributor.authorMody, Pen
dc.contributor.authorvon Hoff, Den
dc.contributor.authorWang-Gillam, Aen
dc.date.accessioned2017-11-21T21:37:36Z-
dc.date.available2017-11-21T21:37:36Z-
dc.date.issued2017-09-
dc.identifier.citation741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx369.124-
dc.identifier.urihttp://hdl.handle.net/10541/620641-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.124/4108827/741PPrognostic-value-of-baselineen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentOncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.